Company Search:
Advanced Search
Sponsored Links
Immutep Ltd Company Snapshot
Immutep Ltd operates within the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Immutep Ltd with three other companies in this sector in AUSTRALIA : Idt Australia Limited. (2020 sales of 14.17 million Australian Dollars [US$10.80 million] ), Pharmaxis Ltd (12.55 million Australian Dollars [US$9.57 million] of which 56% was Mannitol), and Cellmid Limited (7.48 million Australian Dollars [US$5.70 million] of which 79% was Advangen Japan).

Sales Analysis. During the year ended June of 2020, sales at Immutep Ltd were A$13.94 million (US$10.62 million). This is an increase of 131.0% versus 2019, when the company's sales were A$6.03 million. Sales of Cancer Immunotherapy saw an increase of 143.7% in 2020, from A$5.64 million to A$13.74 million.
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Immutep Ltd
  Stock Performance Chart for Immutep Ltd
  Stock Data: Recent Stock Performance:
  Current Price (4/9/2021): .46
(Figures in Australian Dollars)
1 Week 8.3%   13 Weeks 35.8%  
4 Weeks 8.3%   52 Weeks 237.0%  
Immutep Ltd Key Data:
  Ticker: IMM Country: Australia
  Exchanges: ASX Major Industry: Commercial Services & Supplies
    Sub Industry: Commercial Physical Research
  2020 Sales 13,938,824
(Year Ending Jan 2021).
Employees: 19
  Currency: Australian Dollars Market Cap: 295,170,005
  Fiscal Yr Ends: June Shares Outstanding: 648,725,286
  Share Type: Ordinary Closely Held Shares: 35,249,870
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.